Clinical trialNCT03519971CompletedPhase 3Interventional

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

SponsorAstraZenecaEnrollment328Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care \[SoC\] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jeffrey Bradley, MD
AstraZeneca
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

86 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil

Research Site
Barretos, Brazil
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Fortaleza, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil

Czechia

Research Site
Brno, Czechia
Research Site
Ostrava, Czechia
Research Site
Prague, Czechia

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Gyula, Hungary
Research Site
Győr, Hungary
Research Site
Törökbálint, Hungary

India

Research Site
Bangalore, India
Research Site
Chennai, India
Research Site
Gurgaon, India
Research Site
Karamsad, India
Research Site
Mumbai, India
Research Site
Nashik, India
Research Site
New Delhi, India
Research Site
Vadodara, India

Japan

Research Site
Bunkyō City, Japan
Research Site
Fukuoka, Japan
Research Site
Kyoto, Japan
Research Site
Kōtoku, Japan
Research Site
Nagoya, Japan
Research Site
Sayama, Japan
Research Site
Sendai, Japan
Research Site
Yokohama, Japan

Mexico

Research Site
Aguascalientes, Mexico
Research Site
Guadalajara, Mexico
Research Site
Mexico City, Mexico
Research Site
Mérida, Mexico
Research Site
México, Mexico

46 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cisplatin →Durvalumab →Pemetrexed →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Mar 2018
Primary completion: 7 Sept 2023
Completion: 9 Mar 2026
Last update posted: 14 Jul 2026
Registered enrollment: 328
Registry id: NCT03519971

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-004397-34

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.